Kornimate/medical-research-clean huggingface dataset:
combined restylane and triamcinolone acetonide injections for the treatment of alopecia areata

Conditions: Alopecia Areata

Summary: the investigators hypothesize that restylane® could serve as a repair matrix which also maintains il triamcinolone acetonide concentrations at higher levels for a longer period of time in the skin, giving a more sustained local anti-inflammatory effect and thus, arresting the aa process and promoting hair regrowth. furthermore, the combination of restylane® with il triamcinolone acetonide injections may prevent a common side effect, atrophy. with the prevention of scalp atrophy and the preservation of higher concentrations of triamcinolone acetonide for longer periods of time, patients may see a better clinical response for a longer period of time. quality of life may improve as the number of clinic visits decreases as would the number of il corticosteroid injections.


Eligibility criteria:
inclusion criteria: 1. men and women ages 18 and greater. 2. alopecia areata diagnosis in the last two years with extensive scalp involvement, between 74% and 99%, alopecia areata must involve the left and right hemispheres of the scalp. 3. willing to abstain from use of over the counter products and prescription products, other than study medications, which may promote hair growth. 4. willing to abstain from the use of non-steroidal anti-inflammatory medications, aspirin, st. johns wart, and high doses of vitamin e supplementation. 5. subjects are capable of giving informed consent. 6. willing to adhere to protocol, including scalp examinations and photography. exclusion criteria: 1. allergy or intolerance to restylane® or hyaluronate preparations 2. allergy or intolerance to triamcinolone acetonide, 10 mg/cc. 3. underlying disease that might be adversely affected by restylane® or triamcinolone (ex. patients with bleeding disorders). 4. immunosuppressed patients (history of transplantation, cancer, chemotherapy, splenectomy, hiv). 5. pregnant or lactating female. 6. application of topical immunomodulatory or immunosuppressive agent in the preceding 6 weeks. 7. systemic administration of corticosteroid or other systemic treatment (i.e. prednisone) that has immunomodulatory or other immunosuppressive mechanism of action, in the preceding 8 weeks. 8. clinical evidence of secondary skin infection (i.e., folliculitis). 9. other inflammatory or infectious skin disease that might interfere with evaluations during the study. 10. investigational medications within the past 30 days. 11. patients with susceptibility to keloid formation. 12. severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies 13. patients with allergies to gram positive bacterial proteins 14. unable to give consent.
correlation between muscle thickness and inflammation with ventilator use in critically ill patients

Conditions: Ventilation Therapy; Complications

Summary: decrease thickness of diaphragm muscle, cross-sectional area of rectus femoris and biceps brachii muscle, and increase in crp would affect ventilator length of use in critically ill patients in icu


Eligibility criteria:
inclusion criteria: * patients who had modified rankin score \< 4 in 1 month before admitted into icu exclusion criteria: * pregnant women * patients who had intubation more than 24 hours before admitted at icu cipto mangunkusumo hospital * patients who had a history or prior to thoracic or heart surgery 14 days before admission * patients who had severe peripheral muscle dysfunction * patients who had a history of admission in hospital for more than 2 weeks on the last 3 months * patients who predicted will be using ventilator for less than 4 days * patients who suffered acute respiratory distress syndrome (ards) with a ratio of arterial oxygen partial pressure to fractional inspired oxygen (pao2/fio2) less than 200 * patients who declined to participate in this study
effectiveness of vitamin e and hydrogen-rich water on radiation therapy-induced adverse in patients with rectal cancer

Conditions: Radiation-induced Injuries in Patients With Rectal Cancer

Summary: controlled studies investigating the effects of vitamin e or h2 water or comparing their effectiveness on radiation therapy-induced injuries in rc patients are generally lacking. the present study hypothesis the following: (1) pre - radiation therapy administration of vitamin e to patients with rectal carcinoma will provide radioprotection for exposed healthy tissues. (2) consumption of h2 water by patients with rectal carcinoma undergoing rt will reduce the side effects of this modality. (3) rectal cancer patients receiving h2 water will show better biological improvement than those receiving only vitamin e, i.e., h2 water is more effective antioxidant than vitamin e. (4) the proposed radiation countermeasures will not compromise the anti-tumor effects.


Eligibility criteria:
inclusion criteria: * - men or women. * older than 18 years. * histologically proven adenocarcinoma of the rectum. * underwent radiotherapy. * absence of any psychological, and sociological condition that potentially affects the compliance with the study protocol and follow-up schedule. exclusion criteria: * the use of anticoagulant and antiplatelet agents. * any disease of disorder capable of contraindicating the absorption of vitamin e or hydrogen water in the body of a patient being investigated. * no known history of problems absorbing fats (e.g., crohn disease, cystic fibrosis)
monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging

Conditions: Breast Cancer

Summary: the investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. the efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. the researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients.

the investigators are testing the effectiveness of an experimental imaging technology known as diffuse optical spectroscopy imaging in predicting the success of chemotherapy treatment (shrinkage of tumor). diffuse optical spectroscopic imaging measurements are made with a laser breast scanner. this bedside-capable system combines frequency-domain photon migration with steady-state tissue spectroscopy to measure complete(broadband) near-infrared absorption and reduced scattering spectra of breast tissue in vivo. diffuse optical spectroscopy imaging measurements are made by placing the hand-held probe on the tissue surface and moving the probe to discrete locations along a grid pattern at 1.0 cm intervals. the portable high-bandwidth frequency-domain photon migration instrument employs intensity-modulated diode lasers and conventional steady-state lamps as sources and an avalanche photodiode as the detector. the time required to perform an frequency-domain photon migration measurement depends on the desired precision and number of sweeps.

Eligibility criteria:
inclusion criteria: * female, 18 years of age or older, non pregnant or nursing. * diagnosis of breast cancer and will be receiving chemo therapy treatments exclusion criteria: * 18 years of age or younger, pregnant or nursing. * previous treatment including chemo therapy, radiation, surgery, and hormone therapy. * previous diagnosis with other form of cancer.

Keywords: breast cancer
skin sensitivity acupuncture and kinesiotherapy on breast cancer patients subject to chemotherapy with taxans

Conditions: Chemotherapy Effect

Summary: objective: to compare different therapies employing acupuncture needles, silicon pellets and kinesiotherapy in breast cancer patients to taxane chemotherapy cycles. methods:the present study will be carried out at the oncomastology outpatient clinic of the unifesp (federal university of são paulo) gynecology department's discipline of mastology - escola paulista de medicina (epm) and the oncology clinic associated center of oncology, located at rua gabriel monteiro da silva, 454. randomized clinical trial will be conducted to define the treatment. patients will be allocated into three groups (group a: stiper, group b: acupuncture, group c: kinesiotherapy and group d after treatment ) who will receive treatment once a week for eight consecutive weeks. group - s-observation.124 patients will be randomized in one of the three groups, after having signed the free and informed consent form and agreed to participate in the project, will respond to the evaluation form and will be submitted to physical examination. patients will be evaluated in the first and tenth sessions. keywords: acupuncture, breast neoplasm, chemotherapy.

women will be recruited at the oncomastology outpatient clinic of the unifesp (federal university of são paulo) gynecology department's discipline of mastology - escola paulista de medicina (epm) and clínica de oncologistas associados centro integrado de oncologia, located at rua gabriel monteiro da silva, 454. patients will consecutively be selected by order of entry in the chemotherapy recorded in the log and randomized in one of three intervention groups. complying with all the research's ethical aspects, the following procedures will apply: 1st clarify the study's objectives;2nd sign the term of free and informed consent, signed in two ways, as one stays with the patient; 3rd espond to the evaluation form in the following items: socioeconomic aspects, main complaint, family history, personal history, surgical data, pathological anatomy, radiotherapy, chemotherapy, hormone therapy, sensitivity and perimetry;4 th physical exams. completed the fact-taxane questionnaire. patients will be evaluated in the first and tenth sessions.

Eligibility criteria:
inclusion criteria: * women over 18 years old * women submitted to chemotherapy with taxanes * the 1th cycle both neoadjuvant and adjuvant with staging from i to iii no mental changes exclusion criteria: * women with preexisting diseases such as locoregional or distant cancer, previous joint pain, * rheumatic disease, * who are not undergoing chemotherapy with anthracyclics and / or cisplatin * acupuncture in another service in the last three will be excluded.

Keywords: physical activity sensory neuropathy acupuncture depression anxiety skin sensitivity
beneficial effects of probiotics on improvement of gut dysbiosis and ascending cholangitis in patients received pancreaticoduodenectomy

Conditions: Precancerous Lesions

Summary: to determine whether probiotics have beneficial effect on gut dysbiosis and postoperative ascending cholangitis in patients with pancreaticoduodenectomy.

gut dysbiosis and postoperative ascending cholangitis (poac) occurred after pancreaticoduodenectomy (pd). to date, no clinical trial has evaluated the association between gut dysbiosis, poac and probiotics. poac is a common morbidity after pancreaticoduodenectomy or in obstructive jaundice patients with endoscopic retrograde biliary drainage (erbd). it frequently induces longer hospital stay and makes the major obstacle for postoperative chemotherapy. this phenomenon reveals the important role of ampullary vater in control of retrograde bacterial inflow into bile duct. however, the exact difference of gut microbiota after pancreaticoduodenectomy is still unknown. probiotics is reported efficacy in restore the normal flora of gut microbiota. so, this study is to evaluate the effects of probiotics consumption, yugart 2 bottles per day for 1 month on gut microbiota in control of ascending cholangitis before and after pancreaticoduodenectomy through the analysis of microbial community by next generation sequencing.

Eligibility criteria:
inclusion criteria: * subjects with peri-ampullary lesions and scheduled to receive pancreaticoduodenectomy (pd) were designed as experimental group; subjects with pancreatic lesions and scheduled to receive distal pancreatectomy (dp) were designed as control group. * subjects that already received pd for more than 6 months to join the study and aim to evaluate the effect of probiotics on gut microbiota and postoperative ascending cholangitis (poac). * subjects with the amount of two bottles a day (one provided in the morning and the other in the afternoon) for a duration of 4 weeks. exclusion criteria: * subjects are currently participating in any other clinical trials or studies.

Keywords: ampullary pancreas
a controlled trial of plantain powder in infantile diarrhea

Conditions: Diarrhea, Infantile

Summary: green banana has been traditionally used in diarrheal and other diseases. recent studies have shown that green banana is beneficial in children with diarrhea. the purpose of this study is to try green banana in a portable, storable and dosable form in infants with diarrhea. infants with diarrhea and meeting the inclusion criteria will receive either green banana powder or placebo (microcrystalline cellulose). their response will be monitored for 10 days. the subjects, parents and researchers conducting the study will not know whether banana powder or placebo is being given to that particular subject (double blind randomized study). two hundred patients will be enrolled in 24 months.


Eligibility criteria:
inclusion criteria: 1. children between the ages of 5 months and 2 years of age admitted in the inpatient pediatric ward of bhatpara sub divisional hospital. 2. infants with more than 3 stools/day which is more frequent than the usual bowel habit of the study subject 3. the consistency of the stool is such that it takes the shape of the container into which it is put in. 4. duration of symptoms should be less than 14 days. - exclusion criteria: 1. children with bloody diarrhea 2. children with lethargy, fever or other signs of septicemia 3. children with shock. 4. children unable to take medications orally. 5. children with impaired consciousness. 6. children whose parents refuse permission to be included in the study. 7. children who are not usual residents of the area and will not be available for follow up. 8. children with chronic illnesses such as congenital heart disease, renal failure, chronic liver disease, chronic lung disease, inflammatory bowel disease, immune deficiency etc. -

Keywords: diarrhea plantain green banana infants children
treatment of hepatocellular carcinoma with tetrathiomolybdate

Conditions: Carcinoma, Hepatocellular

Summary: hepatocellular carcinoma (hcc) is a deadly tumor for which the incidence is increasing in the united states, primarily due to prevalence of hepatitis c infection. an important aspect of the development of hcc is that it occurs in patients who have underlying cirrhosis of the liver, thereby limiting the therapeutic options. there is potential curative treatment for these patients, such as resection of the tumor lesion and liver transplantation, but these treatments are feasible in a small percent of patients only. furthermore, the majority of the patients with hcc are also not candidates for palliative treatments such as percutaneous ablation of the tumor, chemotherapy or radiation. additionally, it has been shown that these palliative treatment modalities do not alter survival, and are associated with significant risks. therefore, there are no treatment options for most patients with hcc. a new theory has emerged in the fight against cancer through inhibition of angiogenesis (development of new blood vessels). the hypothesis being that if there is no blood supply "feeding" the tumor cells cannot divide or survive. one such approach, pioneered in this institution by drs. george brewer and sofia merajver, is the anticopper approach using the medication tetrathiomolybdate (tm). by creating a mild copper deficiency state, several pathways required for angiogenesis are inhibited. they performed a phase i trial in which patients with metastatic cancer were treated with tm resulting in decrease tumor vascularity. tm had excellent safety profile in this patient population. hcc is well known to be a hypervascular tumor. an antiangiogenesis approach might provide a novel treatment for this hcc. this is a pilot study of 10 patients with hcc who are not candidates for curative surgical therapy with resection or liver transplantation, nor for ablative techniques. patients seen in the general liver clinic and liver transplant clinic who have an overall good performance status, with an expected survival of more than 6 months will be enrolled. after an initial evaluation, they will be given 120 mg/day of tm in divided doses for one year. the size and vascularity of the tumor will be evaluated by magnetic resonance imaging (mri). the primary outcome of this study is to prevent tumor progression.


Eligibility criteria:
inclusion criteria: * patients with definite diagnosis of hcc based on a dynamic mri revealing a vascular mass in the liver and histologic confirmation of hcc. * patients who are not candidates for surgical resection, olt or radiofrequency ablation. * patients with no prior treatment for hcc. * patients with extrahepatic spread and/or vascular invasion are permissible.

Keywords: molybdenum
immune response in dialysis patients vaccinated against covid-19

Conditions: Covid19; Chronic Kidney Disease 5D

Summary: this is a prospective cohort study aimed to evaluate short- and mid-term immune response after sars-cov-2 vaccination using gam-covid-vac (sputnik v) vaccine in dialysis patients compared to the control group (medical staff).

background and aims: patients receiving kidney replacement therapy with dialysis are at high risk of infection and death from covid-19. there is a lack of evidence whether sars-cov-2 vaccination is effective in this immunocompromised group. study design: this is a prospective cohort study. two cohorts will be included: dialysis patients and controls (medical staff), both vaccinated with gam-covid-vac (sputnik v) vaccine. blood samples will be collected at 28 days and 22 weeks after after the second sars-cov-2 vaccine dose administration. the primary outcome is the level of sars-cov-2 igg antibodies on day 28 after the second vaccination as compared to controls. the secondary outcomes are: 1) the level of sars-cov-2 igg antibodies on week 22 after the second vaccination; 2) t cell subtype immunity measured by sars-cov-2 interferon-γ release assays (igra) 28 days and 22 weeks after the second vaccination.

Eligibility criteria:
inclusion criteria: * age of 18 years or older * previously vaccinated against sars-cov-2 with two administrations of gam-covid-vac (sputnik v) vaccine * written informed consent. exclusion criteria: * a history of previous covid-19 disease * active malignancy of any localization * human immunodeficiency virus (hiv) infection * maintenance treatment with immunosuppressive therapy.
covid-19 vaccine uptake trial

Conditions: Vaccination Refusal; COVID-19

Summary: the goal of this study is to assess the best covid-19 vaccine uptake strategy among students, staff and household members that have not been vaccinated. there is a multitude of recommendations present that highlight different vaccination strategy; however, it is still unclear which strategy is best to increase covid-19 vaccination rates. we will compare the effectiveness and acceptance of two different communication strategies among unvaccinated students, staff, and their household members.

a sequential multiple assignment randomized trial (smart) will be conducted to assess two strategies to increase covid-19 vaccine uptake. the two strategies that will be assessed are a text message with a link to an information website and peer-based motivational interview. if individuals do not seek vaccination after the first intervention, they will again be randomized into the same two interventions. this will allow for testing of both interventions as well as understanding if the use of a more intense intervention (two 'doses') is optimal for vaccine uptake. in addition, sars-cov-2 saliva-based testing will be conducted among students, staff, and household members from the summer of 2022 through the first semester of the 2022-2023 school year. as the pandemic is in its third year, the use of testing among students, staff, and their household members will be assessed individuals are eligible to be tested multiple times and the testing will occur along different timelines.

Eligibility criteria:
inclusion criteria: 1. is not up to date with their covid-19 vaccinations per cdc guidelines 2. is considered eligible by the cdc at the time of enrollment to receive a covid-19 vaccine 3. is a staff, student, or household member of staff or student of one of the participating school districts or a resident of st. louis city or st. louis county exclusion criteria: 1. is currently up to date with their covid-19 vaccinations per cdc guidelines 2. ineligible to receive any covid-19 vaccine due to medical history or age 3. is not a staff or student, or household member of staff or student of one of the participating school districts and is not a resident of st. louis city or st. louis county 4. participant (or their parents/lar) do not provide consent.
a prospective, open label, treatment use study of patient safety following transfusion of intercept platelet components

Conditions: Chikungunya Virus; Dengue Virus

Summary: the rationale for a treatment use investigational device exemption (ide) of intercept pcs is to address current gaps in platelet transfusion safety in selected geographic regions. the objective is to provide access to intercept pcs for patients who might be at risk of transfusion-transmitted infection (tti) due to chikungunya virus (chikv) and dengue virus (denv) in regions in which a substantial proportion of the population has been infected or is at risk of infection by these pathogens (petersen 2014); and the risk of asymptomatic infection among qualified blood donors is recognized (stramer 2012, adda 2014). the study is designed as a prospective, open label, multi-center, observational study to evaluate the safety and efficacy of intercept platelet components.

upon written informed consent, patients will be transfused with study pcs according to local practices. each patient will be supported with platelets as clinically indicated in a manner that is consistent with the local standard of care. the study will be conducted in two phases. during the pilot phase, patients will sign informed consent to have study data collected following transfusion with conventional pcs. the objective of the pilot phase is to evaluate study logistics and data collection methods. during the intercept treatment use phase, patients will sign informed consent to receive intercept pcs, provide blood samples, and collect study data (demographics, transfusion data, and safety data).

Eligibility criteria:
inclusion criteria: * patients with a serious disease expected to require or requiring a transfusion of platelet component(s) * patient population as defined by each investigator and their institutional review board (irb). * patient provides written informed consent exclusion criteria * documented allergy to psoralens * neonatal patients treated with phototherapy devices that emit wavelengths less than 425 nm due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. * pregnant women in their third trimester of pregnancy (due to possibility the neonate may need bilirubin light treatment after birth).

Keywords: chikungunya virus chikv dengue virus denv pathogen inactivation platelets puerto rico